Loading clinical trials...
Loading clinical trials...
A Phase I/IIa Clinical Study Evaluating the Bispecific Antibody-Drug Conjugate VBC103 Targeting Nectin-4 and TROP2 in Subjects With Advanced Malignant Solid Tumors
Conditions
Interventions
VBC103
Locations
1
China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Start Date
December 4, 2025
Primary Completion Date
December 1, 2027
Completion Date
December 1, 2028
Last Updated
December 30, 2025
Lead Sponsor
VelaVigo Bio Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions